On 1 December 2025, it has been announced that Santersus AG, a Switzerland-based innovative therapeutic aphresis company, completed a Series A financing round, led by Norcliffe Capital, a UK based Life Sciences investment manager, with participation from Terumo Ventures. The financing will support the advancement of Santersus' NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.
In addition, Santersus has entered a strategic collaboration with Terumo Blood and Cell Technologies to advance NucleoCapture™ for the treatment of sepsis, a disease that kills 11M people worldwide each year.
Pestalozzi advised Norcliffe Capital on matters of Swiss law in connection with the Series A financing, alongside Burness Paull.